Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002770330 | SCV003024006 | uncertain significance | EGFR-related lung cancer | 2023-11-02 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with arginine, which is basic and polar, at codon 1124 of the EGFR protein (p.His1124Arg). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with EGFR-related conditions. ClinVar contains an entry for this variant (Variation ID: 1983552). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV005333339 | SCV005998145 | uncertain significance | Hereditary cancer-predisposing syndrome | 2025-01-03 | criteria provided, single submitter | clinical testing | The p.H1124R variant (also known as c.3371A>G), located in coding exon 28 of the EGFR gene, results from an A to G substitution at nucleotide position 3371. The histidine at codon 1124 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |